Findings

What do systematic reviews say?

2 questions · 2 findings · 2 reviews · Kidney and Transplant

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 1 · 50%Moderate 1 · 50%High 0 · 0%

Extended vs short‐duration valganciclovir

Total treatment‐related adverse effects · solid organ transplant recipients

Extended showed no clear difference in total treatment‐related adverse effects compared with short‐duration valganciclovir (moderate certainty).

1 finding from 1 review

Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients 2024 · Cochrane Headline outcomes only
RR 1.16 [0.97, 1.4]
2 studies · 456 participants
Moderate

Muromonab‐CD3 (T cell) vs other antibody (stratified by comparator)

Neurological adverse effects · kidney transplant recipients: first rejection episode

Muromonab‐CD3 (T cell) may leads to higher treatment adverse events: neurological side effects compared with other antibody (stratified by comparator) (low certainty).

1 finding from 1 review

Polyclonal and monoclonal antibodies for treating acute rejection episodes in kidney transplant recipients 2017 · Cochrane Headline outcomes only
RR 13.1 [1.43, 120.05]
2 studies · 132 participants
Low